Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. more
Time Frame | VYGR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.29% | -2.12% | -3% |
1-Month Return | 7.28% | -3.42% | -0.73% |
3-Month Return | -8% | -11.13% | 2.87% |
6-Month Return | -26.19% | -5.74% | 7.17% |
1-Year Return | -27.58% | 3.97% | 25.31% |
3-Year Return | 96.92% | 1.05% | 28.38% |
5-Year Return | -58.99% | 34.37% | 81.89% |
10-Year Return | -67.61% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 104.39M | 171.13M | 37.41M | 40.91M | 250.01M | [{"date":"2019-12-31","value":41.76,"profit":true},{"date":"2020-12-31","value":68.45,"profit":true},{"date":"2021-12-31","value":14.97,"profit":true},{"date":"2022-12-31","value":16.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 119.73M | 108.75M | 73.79M | 6.19M | 4.44M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":90.83,"profit":true},{"date":"2021-12-31","value":61.63,"profit":true},{"date":"2022-12-31","value":5.17,"profit":true},{"date":"2023-12-31","value":3.71,"profit":true}] |
Gross Profit | 104.39M | 62.38M | 37.41M | 40.91M | 245.57M | [{"date":"2019-12-31","value":42.51,"profit":true},{"date":"2020-12-31","value":25.4,"profit":true},{"date":"2021-12-31","value":15.24,"profit":true},{"date":"2022-12-31","value":16.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 36.45% | 100.00% | 100.00% | 98.22% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":36.45,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.22,"profit":true}] |
Operating Expenses | 156.07M | 143.74M | 111.03M | 91.74M | 127.99M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.1,"profit":true},{"date":"2021-12-31","value":71.14,"profit":true},{"date":"2022-12-31","value":58.78,"profit":true},{"date":"2023-12-31","value":82.01,"profit":true}] |
Operating Income | (51.68M) | 27.38M | (73.62M) | (50.84M) | 122.01M | [{"date":"2019-12-31","value":-42.35,"profit":false},{"date":"2020-12-31","value":22.44,"profit":true},{"date":"2021-12-31","value":-60.34,"profit":false},{"date":"2022-12-31","value":-41.66,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 14.54M | 11.02M | 2.03M | 6.24M | 23.45M | [{"date":"2019-12-31","value":62.01,"profit":true},{"date":"2020-12-31","value":46.99,"profit":true},{"date":"2021-12-31","value":8.66,"profit":true},{"date":"2022-12-31","value":26.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (43.60M) | 36.74M | (71.20M) | (46.39M) | 133.74M | [{"date":"2019-12-31","value":-32.6,"profit":false},{"date":"2020-12-31","value":27.47,"profit":true},{"date":"2021-12-31","value":-53.24,"profit":false},{"date":"2022-12-31","value":-34.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | (2.77M) | (1.66M) | (5.17M) | 16.00K | 1.41M | [{"date":"2019-12-31","value":-196.38,"profit":false},{"date":"2020-12-31","value":-117.83,"profit":false},{"date":"2021-12-31","value":-366.83,"profit":false},{"date":"2022-12-31","value":1.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (40.83M) | 38.40M | (66.03M) | (46.41M) | 132.33M | [{"date":"2019-12-31","value":-30.86,"profit":false},{"date":"2020-12-31","value":29.02,"profit":true},{"date":"2021-12-31","value":-49.9,"profit":false},{"date":"2022-12-31","value":-35.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (43.60M) | 36.74M | (71.20M) | (46.41M) | 132.33M | [{"date":"2019-12-31","value":-32.95,"profit":false},{"date":"2020-12-31","value":27.76,"profit":true},{"date":"2021-12-31","value":-53.8,"profit":false},{"date":"2022-12-31","value":-35.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (40.83M) | 36.74M | (66.03M) | (46.41M) | 132.33M | [{"date":"2019-12-31","value":-30.86,"profit":false},{"date":"2020-12-31","value":27.76,"profit":true},{"date":"2021-12-31","value":-49.9,"profit":false},{"date":"2022-12-31","value":-35.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | (1.27) | 0.95 | (1.90) | (1.22) | 3.09 | [{"date":"2019-12-31","value":-41.1,"profit":false},{"date":"2020-12-31","value":30.74,"profit":true},{"date":"2021-12-31","value":-61.49,"profit":false},{"date":"2022-12-31","value":-39.48,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
VYGR | |
---|---|
Cash Ratio | 7.81 |
Current Ratio | 8.45 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VYGR | |
---|---|
ROA (LTM) | 1.57% |
ROE (LTM) | 10.22% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VYGR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VYGR | |
---|---|
Trailing PE | 8.71 |
Forward PE | NM |
P/S (TTM) | 1.92 |
P/B | 0.95 |
Price/FCF | NM |
EV/R | 0.09 |
EV/Ebitda | 1.02 |
PEG | NM |
Voyager Therapeutics Inc (VYGR) share price today is $5.75
Yes, Indians can buy shares of Voyager Therapeutics Inc (VYGR) on Vested. To buy Voyager Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VYGR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Voyager Therapeutics Inc (VYGR) via the Vested app. You can start investing in Voyager Therapeutics Inc (VYGR) with a minimum investment of $1.
You can invest in shares of Voyager Therapeutics Inc (VYGR) via Vested in three simple steps:
The 52-week high price of Voyager Therapeutics Inc (VYGR) is $11.72. The 52-week low price of Voyager Therapeutics Inc (VYGR) is $5.19.
The price-to-earnings (P/E) ratio of Voyager Therapeutics Inc (VYGR) is 8.7727
The price-to-book (P/B) ratio of Voyager Therapeutics Inc (VYGR) is 0.95
The dividend yield of Voyager Therapeutics Inc (VYGR) is 0.00%
The market capitalization of Voyager Therapeutics Inc (VYGR) is $316.28M
The stock symbol (or ticker) of Voyager Therapeutics Inc is VYGR